Saturday 17 October 2026
Export LMRI’s income statement to Excel — free account
Lumexa Imaging Holdings, Inc.
LMRI Healthcare Medical Devices
Lumexa Imaging Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 7.82% from fiscal 2024. In the quarter to June 2026, revenue grew 7.82%, EPS grew 127.1% and free cash flow grew 257.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
10.78
0.00
0.00%
Follow LMRI
| Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 |
P/S ratio |
0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | 0.96 |
Altman Z″-Score (non-manufacturers) |
— | (0.81) | (0.09) |
P/FCF ratio |
128.20 | 128.20 | 0.00 |
P/Operating CF |
621.15 | 621.15 | 76.91 |
Beneish M-Score |
— | — | (2.67) |
P/B ratio |
7.97 | 7.97 | 2.24 |
Price to Tangible BV |
7.97 | 7.97 | 0.00 |
EV/Sales |
0.00 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 |
EV/Operating CF |
37.36 | 37.36 | 46.17 |
EV/FCF |
246.79 | 246.79 | (293.46) |
Quick Ratio |
— | 0.93 | 1.17 |
Current Ratio |
— | 0.99 | 1.27 |
Net Debt/EBITDA |
0.00 | 10.05 | 5.06 |
Debt/Assets |
0.00% | 72.86% | 49.04% |
Debt/Equity |
0.00 | 7.53 | 1.48 |
Asset Turnover |
0.00 | 1.14 | 0.60 |
Operating CF/Net income |
(0.31) | (0.43) | (0.36) |
Capex/Depreciation |
(0.25) | (0.43) | (0.34) |
Interest Coverage |
0.16 | 0.41 | 0.83 |
| 0.00% | 0.00% | (12.60%) | |
| 0.00% | (11.27%) | (2.74%) | |
ROIC |
0.00% | 2.55% | 4.39% |
Return on Tangible Assets |
0.00% | (78.42%) | (24.43%) |
Average Days of Receivables |
0.00 | 52.31 | 53.82 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
5.89% | 7.42% | 8.84% |
Intangible Assets out of Total Assets |
0.00 | 0.51 | 0.48 |
Share Based Compensation of Revenue |
5.91% | 5.97% | 4.07% |
Graham Net Nets |
(1.04) | (1.04) | (0.72) |
Graham Number |
0.00 | 0.00 | 0.00 |
Earnings Yield |
(9.94%) | (9.94%) | (9.94%) |
Free Cash Flow Yield |
0.78% | 0.78% | (0.55%) |
Revenue per Share |
13.48 | 13.66 | 14.41 |
Operating CF per Share |
0.54 | 0.59 | 0.24 |
Capex per Share |
(0.35) | (0.39) | (0.29) |
Free Cash Flow per Share |
0.19 | 0.19 | (0.05) |
Cash per Share |
0.00 | 0.38 | 0.83 |
Shareholders Equity per Share |
0.00 | 2.33 | 8.26 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | 2.33 | 8.26 |
Free Cash Flow |
13.51 | 13.32 | (3.76) |
Working Capital |
— | (1.14) | 48.07 |
Capital Expenditures |
(24.01) | (27.41) | (20.83) |
Net Current Asset Value |
0.00 | (1,336.39) | (951.17) |
EV/EBIT |
0.00 | 0.00 | 0.00 |
Capex to Sales |
0.03 | 0.03 | 0.02 |
Price to Operating Income |
0.00 | 0.00 | 0.00 |
| Other line items | |||
Depreciation/Fixed assets |
0.00 | 0.52 | 0.43 |
Cash ROIC |
0.00% | 0.95% | (0.25%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 7.13 |
Accounts Payable Turnover |
0.00 | 0.00 | 23.16 |
Inventory Turnover |
0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 12.80 | 18.92 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 |
Average Receivables |
— | — | 143.42 |
Average Payables |
— | — | 37.37 |
Average Assets |
— | 835.28 | 1,717.56 |
Average Common Equity |
— | — | 373.89 |
Columns are period end dates